Roche licensing agreement profiled in Networks of Centres of Excellence of Canada impact story
The Networks of Centres of Excellence (NCE) of Canada published an impact story about the recent licensing agreement between Roche and UBC. It describes PC-TRiADD's role in assisting the transition from discovery to intellectual property (IP) to commercialization.
Click here to read the article at the NCE's website.
Potential prostate cancer treatment developed in B.C. gets big boost
A potential treatment for advanced prostate cancer developed by the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche, marking UBC’s largest licensing agreement to date.
Destructive disease shows potential as a cancer treatment
Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.
This new approach, which halted the growth of various tumours in mice, was based on a discovery by collaborators at the University of Copenhagen. While exploring why pregnant women are particularly susceptible to malaria, they found that the mosquito-borne parasite produces a protein that binds to a particular type of sugar molecule in the placenta.
September 26, 2014 - Prostate Cancer Canada today annouced the results of their funding decision in their Translation Acceleration Grant competition TAG2: Novel Therapeutics for Advanced Disease. This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for projects aimed at eliminating advanced disease from affected men. Co-lead by Drs.
SHENZHEN, China and VANCOUVER, British Columbia, September 12, 2014 – BGI, the world’s largest genomics organization, based in China, and The Vancouver Prostate Centre (VPC), a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including precision oncology.
With the awarding of $14.5M under the Canadian government’s Networks of Centres of Excellence (Centres of Excellence for Commercialization and Research (CECR)) Program, as announced earlier this morning by the Honourable Ed Holder, Minister of State for Science and Technology, Accel-Rx - Canada’s Health Sciences Accelerator is officially launched.The Accel-Rx Health Sciences Accelerator is a national organization focused on maximizing new health sciences company creation, and ensuring start-ups have the resources they need to enable them to stay and grow in Canada and give rise to a new gen
BIO International Conference, San Diego – June 25, 2014: BDC Venture Capital and the Accel-Rx Health Sciences Accelerator (Accel-Rx) announced today a collaboration to provide critical seed funding to new and emerging Canadian health sciences companies. Together, Accel-Rx, BDC Venture Capital, and CDRD Ventures Inc.
Funding announced for Dr. Yuzhuo Wang’s next generation prostate cancer research
VANCOUVER – Today the Canadian Institutes of Health Research (CIHR) is announcing it will match funding from BRI Biopharmaceutical Research Inc (BRI) for a total of $750,000 over a three year Industry Partnered Collaborative Research Grant. This money will enable ongoing research collaborations between Dr. Yuzhuo Wang’s laboratories at the BC Cancer Agency and Vancouver Prostate Centre (VPC), and BRI to develop new state-of-the-art experimental cancer models.Read the press release here (91 kb PDF, opens in new window) Dr. Wang, Dr.
Dr. Gleave to give MSFHR-VCHRI lecture on the PC-TRiADD Model
The Michael Smith Foundation for Health Research (MSFHR) and the Vancouver Coastal Research Institute are pleased to present a lecture by one of British Columbia’s most innovative scientists — a man who has bridged the gap between clinical research and new commercial treatments for disease. Dr. Martin Gleave is the most recent recipient of the MSFHR Aubrey J.
Dr. Kim Chi recieves a BC Cancer Agency Clinician Researcher Award
Dr. Kim Chi is one of two recipients of the BC Cancer Agency Clinician Researcher Award, funded by BC Cancer Foundation donors.Selected by their peers from a high calibre of applicants, Dr. Chi and Dr. David W. Scott were awarded a cumulative $1.5 million over five years. Dr. Chi's project will focus on translational research in prostate cancer, while Dr. Scott will further investigate treatment failure in B cell lymphoid cancers.